Product
Somavaratan
1 clinical trial
1 indication
Indication
Growth DisordersClinical trial
Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone DeficiencyStatus: Completed, Estimated PCD: 2017-08-23